Search

Author/Creator Cremolini, C

2. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (1st October 2019)

Authors:
Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
1969
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LBA-007Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC. (2nd July 2019)

Authors:
Cremolini, C; Antoniotti, C; Lonardi, S; Rossini, D; Morano, F; Cordio, S; Bergamo, F; Marmorino, F; Maiello, E; Passardi, A; Masi, G; Tamburini, E; Santini, D; Grande, R; Zaniboni, A; Granetto, C; Murgioni, S; Aprile, G; Delliponti, L; Boni, L
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA20TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). (23rd October 2018)

Authors:
Cremolini, C; Antoniotti, C; Lonardi, S; Rossini, D; Pietrantonio, F; Cordio, S S; Murgioni, S; Marmorino, F; Maiello, E; Passardi, A; Masi, G; Tamburini, E; Santini, D; Grande, R; Zaniboni, A; Granetto, C; Loupakis, F; Delliponti, L; Boni, L; Falcone, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018)

Authors:
Rossini, D; Cremolini, C; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Bergamo, F; Danesi, R; Cardellino, G; Tamburini, E; Dell'Aquila, E; Strippoli, A; Masi, G; Tonini, G; Negri, F; Corsi, D; Pella, N; Intini, R; Falcone, A; Santini, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019)

Authors:
Zucchelli, G; Marmorino, F; Rossini, D; Aprile, G; Casagrande, M; Lonardi, S; Murgioni, S; Dell'Aquila, E; Tomasello, G; Moretto, R; Antoniotti, C; Borelli, B; Urbano, F; Ronzoni, M; Zaniboni, A; Manglaviti, S; Buonadonna, A; Ritorto, G; Masi, G; Allegrini, G
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018)

Authors:
Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗